Navigation Links
MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
Date:10/1/2007

believes that its sirolimus product may serve as a potentially highly-efficacious therapeutic for a wide range of ocular diseases and conditions, including the treatment and prevention of wet AMD.

As the active pharmaceutical ingredient in the FDA-approved products Rapamune(R) and CYPHER(R) Sirolimus-eluting Coronary Stent, sirolimus has been safely administered to humans for more than six years. MacuSight has developed a proprietary minimally-invasive, sustained administration approach for its novel liquid sirolimus formulation which it believes will provide the product with significant competitive advantages related to convenience, ease-of-use, compliance and safety.

About Diabetic Macular Edema

Diabetic macular edema (DME) is a serious manifestation of diabetic retinopathy that involves retinal swelling brought on by the leaking of fluid from small blood vessels within the macula. As the condition develops, central vision becomes blurred. DME can progress fairly rapidly and over just a few years can lead to permanent visual loss. There is a significant unmet need to both reverse the visual loss associated with DME and to help delay the progression of this condition.

About MacuSight

MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost- effectiveness of its product candidates.

The company's lead development program is centered
'/>"/>

SOURCE MacuSight, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... VIEW, Calif., Dec. 17 Frost ... 2009 North American Healthcare Innovation Award in ... (IntelligentMDx) for its commitment to providing innovative ... diagnostics. Since its incorporation in 2004, IntelligentMDx ... bioinformatics approach to make tests that are ...
(Date:12/17/2009)... Dec. 17 Decision Resources, one of ... on pharmaceutical and healthcare issues, finds that over ... is a high need for diabetes drugs with ... say there is a high need for additional ... agents with excellent glucose lowering ability and physicians ...
(Date:12/16/2009)... 17 Cell Therapeutics, Inc. (CTI) ... on February 10, 2010 the U.S. Food ... (ODAC) will review the New Drug Application ... relapsed/refractory aggressive non-Hodgkin,s lymphoma (NHL). ODAC is ... data concerning the efficacy and safety of ...
Breaking Medicine Technology:Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 2Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 3Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 4Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 5Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4Mars Lends Sweet Support in Fight Against Breast Cancer Through Its M 26amp 3BMs 28R 29 And Dove 28R 29 Chocolate Brands as Well as Its Celebrated Ra 59630 1Mars Lends Sweet Support in Fight Against Breast Cancer Through Its M 26amp 3BMs 28R 29 And Dove 28R 29 Chocolate Brands as Well as Its Celebrated Ra 59630 2Mars Lends Sweet Support in Fight Against Breast Cancer Through Its M 26amp 3BMs 28R 29 And Dove 28R 29 Chocolate Brands as Well as Its Celebrated Ra 59630 3Smart for Life 28TM 29 Center Opens in Ottawa 59627 1Smart for Life 28TM 29 Center Opens in Ottawa 59627 2Haemonetics Sets Date for Second Quarter Fiscal Year 2010 Earnings Release 3A November 2 2009 59624 1
(Date:12/17/2009)... have improved, but Americans fall down on prevention, ... -- While physicians and surgeons are getting better ... too many Americans are ignoring the basic rules ... the American Heart Association. , Topping the list: ... fact, 59 percent of adults surveyed last year ...
(Date:12/17/2009)... results suggest they might be more likely to try ... -- American teens believe that smoking cigarettes is riskier ... government report shows. , That perception may increase the ... the report authors said. , "We are on the ... raising awareness among teens about the dangers of other ...
(Date:12/17/2009)... to access trusted medical information using virtually any smart phone ... ... 17, 2009 -- Skyscape, Inc., the world’s most trusted source ... has launched a mobile clinical decision application on the Google ... on most smart phone devices, making the ability for medical ...
(Date:12/17/2009)... YORK, Dec. 17 Reportlinker.com announces ... available in its catalogue: ,, http://www.reportlinker.com/p0169956/Top-Ten-Worlds-Leading-Animal-Health-Companies.html ... to provide the animal health industry executives ... insight, critical to the development and implementation ... study,s major objectives include: ,, ...
(Date:12/17/2009)... 17 Today, CDC,s Morbidity and Mortality ... the number of state-level epidemiologists has decreased steadily ... 10% since 2006. There was also a substantial ... period, including epidemiology capacity for bioterrorism and emergency ... such as occupational health, substance abuse, and oral ...
Breaking Medicine News(10 mins):Health News:Obesity, Inactivity Keeping Heart Health Stats Down 2Health News:Obesity, Inactivity Keeping Heart Health Stats Down 3Health News:Teens Think Smoking More Dangerous Than Drinking, Drugs 2Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 2Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 3Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 4Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 2Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 3Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 4Health News:CSTE National Assessment Finds Critical Public Health Disease Surveillance Capacity Lacking 2
... ANSYS, Inc.,(Nasdaq: ANSS ), a global ... product development processes, today announced it is a,sponsor ... the Carnegie Museum of,Natural History in Pittsburgh. This ... feature scientifically accurate, immersive environments that are,composed of ...
... (http://www.NBTY.com ), a leading global manufacturer and marketer ... the,presentation by Harvey Kamil, President and Chief Financial Officer ... Las Vegas on,Wednesday, March 19, 2008., The presentation ... Company Web,site, http://www.nbty.com on Wednesday, March 19, ...
... receptor believed ... in Crohn,s disease -, CAMBRIDGE, Mass., March 17 ... of,MLN3126, a new product candidate, from the Company,s discovery engine ... a,chemokine receptor known to be important in the migration of ...
... in Published Studies Now Available to the ... Posit Science(R) Corporation,today announced the release of ... speeds up and sharpens the brain,s ability ... improves not just visual,processing abilities, but also ...
... Fla., March 17 Researchers will unveil ... has been shown in numerous,published studies to ... improve the performance of daily living tasks ... Science(R) Corporation, a San,Francisco-based neuroscience company, will ...
... research team supported by the National Institutes of ... Allergy and Infectious Diseases (NIAID) has identified chemical ... schistosomiasis, a parasitic disease that afflicts more than ... today in the advance online publication of the ...
Other Medicine News:Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 2Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 3Health News:NBTY to Web Cast Presentation at Citigroup Small and Mid-Cap Conference 2Health News:Millennium Expands IBD Franchise with Addition of New Development Candidate 2Health News:Millennium Expands IBD Franchise with Addition of New Development Candidate 3Health News:New Brain Training Program Improves Quality of Life 2Health News:New Brain Training Program Improves Quality of Life 3Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 2Health News:New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 3Health News:Scientists identify new leads for treating parasitic worm disease 2Health News:Scientists identify new leads for treating parasitic worm disease 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: